Scientific article

Sélection d'un médicament dans une classe thérapeutique donnée : l'exemple des «inhibiteurs de l'HMG-CoA réductase»

Published inRevue médicale suisse, vol. 1, no. 14, p. 949-953
Publication date2005

The HMG-CoA reductase inhibitors have similar therapeutic targets and indications. However, their potential pharmacokinetic drug-drug interaction profile may play a significant role in their safety profile in polymedicated and polymorbid patients and can serve as a selection criterion. If their utility is clearly demonstrated in selected conditions, their safety profile remains of concern. Beside dose-related hepatic and muscular injury, other rare and important adverse drug reactions have been reported after prolonged administration such as polyneuropathy, fibrotic interstitial pulmonary disease and lupus-like syndrome. Teratogenicity has also been associated with statin therapy.

  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use
Citation (ISO format)
GIRARDIN, François, DESMEULES, Jules Alexandre, DAYER, Pierre. Sélection d’un médicament dans une classe thérapeutique donnée : l’exemple des «inhibiteurs de l’HMG-CoA réductase». In: Revue médicale suisse, 2005, vol. 1, n° 14, p. 949–953.
ISSN of the journal1660-9379

Technical informations

Creation11/03/2016 10:41:00 AM
First validation11/03/2016 10:41:00 AM
Update time03/15/2023 12:56:30 AM
Status update03/15/2023 12:56:30 AM
Last indexation01/16/2024 10:17:07 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack